Randolph Geslani, MD
Neurology · Lehigh Acres, FLNPI 1760442057
Payments from drug & device makers
Across 584 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Bayer$2K
- AbbVie$1K
- Biogen$968
- Neurocrine Biosciences, Inc.$878
- UCB, Inc.$797
- plus $3K from 30 others
What the payments were for
- Consulting fees$1,0809%
- Travel & lodging$1,34212%
- Food & beverage$8,83077%
- Education$2312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 182 | $2,610 |
| Bayer | 10 | $2,231 |
| AbbVie(2 entities) | 74 | $1,182 |
| Biogen | 35 | $968 |
| Neurocrine Biosciences, Inc. | 55 | $878 |
| UCB, Inc. | 44 | $797 |
| Avanir Pharmaceuticals, Inc. | 42 | $334 |
| SK Life Science, Inc. | 18 | $307 |
| Novartis | 15 | $279 |
| Eisai Inc. | 14 | $241 |
| Lilly USA, LLC | 12 | $196 |
| Otsuka America Pharmaceutical, Inc. | 13 | $169 |
| Bristol Myers Squibb | 8 | $166 |
| E.r. Squibb & Sons, L.L.C. | 7 | $137 |
| Acorda Therapeutics, Inc | 5 | $118 |
| Amgen | 6 | $112 |
| Sunovion Pharmaceuticals Inc. | 7 | $92 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Pfizer | 3 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Johnson & Johnson | 3 | $48 |
| Neurelis, Inc. | 3 | $47 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Lundbeck LLC | 2 | $44 |
| Genentech USA, Inc. | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Zyla Life Sciences, Inc. | 1 | $23 |
| Upsher-smith Laboratories LLC | 2 | $23 |
| Merck | 1 | $22 |
| Livanova USA, Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Sumitomo Pharma America, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,484 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 205 | $1,925,561 |
| Austedo XrDeutetrabenazine | 117 | $1,511,259 |
| NuedextaDextromethorphan Hbr/Quinidine | 98 | $138,469 |
| VumerityDiroximel Fumarate | 13 | $111,540 |
| QuliptaAtogepant | 101 | $110,459 |
| Kesimpta PenOfatumumab | 11 | $110,236 |
| Nurtec OdtRimegepant Sulfate | 74 | $107,563 |
| IngrezzaValbenazine Tosylate | 12 | $100,471 |
| AptiomEslicarbazepine Acetate | 58 | $74,248 |
| UbrelvyUbrogepant | 58 | $73,198 |
| InbrijaLevodopa | 17 | $60,148 |
| BriviactBrivaracetam | 39 | $55,176 |
| Teriflunomide | 12 | $35,134 |
| FycompaPerampanel | 16 | $30,774 |
| Emgality PenGalcanezumab-Gnlm | 36 | $25,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,610 | $3,436,820322 claims |
| AbbVieQulipta, Ubrelvy, Linzess, Vraylar | $1,182 | $218,357200 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $334 | $138,46998 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $878 | $122,22526 claims |
| BiogenVumerity | $968 | $111,54013 claims |
| PfizerNurtec Odt | $55 | $107,56374 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $92 | $74,24858 claims |
| UCB, Inc.Briviact, Neupro | $797 | $73,28451 claims |
| Acorda Therapeutics, IncInbrija | $118 | $60,14817 claims |
| Eisai Inc.Fycompa, Dayvigo | $241 | $35,79931 claims |
| MerckBelsomra | $22 | $16,95939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.
Other neurology in Lehigh Acres
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.